

Pursuant to the provisions of article 226 of the Law 6/2023, of March 17, on Securities Markets and Investment Services, Grifols S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

INSIDE INFORMATION

As a continuation of the Inside Information note filed by Grifols on 31 March 2025, Grifols informs that today the German federal financial supervisory authority, the Bundesanstalt für Finanzdienstleistungsaufsicht ("**BaFin**"), approved the publication of the offer document submitted by its fully owned subsidiary Grifols Biotest Holdings GmbH with the terms and conditions of the public delisting purchase offer launched to all shareholders of Biotest AG ("**Biotest**") to acquire all ordinary shares of Biotest which are not already directly or indirectly held by Grifols Biotest Holdings GmbH for a price of EUR 43.00 per ordinary share and all non-voting preference shares of Biotest which are not already directly or indirectly held by Grifols Biotest Holdings GmbH for a price of EUR 30.00 per preference share (the "**Offer Document**").

As stated in Section 5 of the Offer Document, the initial acceptance period is initiated today with the publication of the Offer Document and runs from today until 6 June 2025, 24:00 hrs (Frankfurt am Main local time) / 18:00 hrs (New York local time).

The Offer Document, as well as any other documentation and information which is required to be published by applicable legislations, will be available at the link <https://www.grifols.com/en/biotest-acquisition-offer> (in German, together with a non-binding English translation). Further, copies of the Offer Document (in German) are available for issue free of charge at Deutsche Bank Aktiengesellschaft, TAS, Post-IPO Services, Taunusanlage 12, 60325 Frankfurt am Main, Germany (inquiries by email to dct.tender-offers@db.com).

In Barcelona, on 6 May 2025.

Nuria Martín Barnés
Secretary to the Board of Directors